TRAP1: a viable therapeutic target for future cancer treatments?

References

• Kumalo HM, Bhakat S, Soliman ME. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective. Chem Biol Drug Des. 2015;86(5):1131–1160.
   PubMed Web of Science ®Google Scholar
• McClellan AJ, Xia Y, Deutschbauer AM, et al. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell. 2007;131(1):121–135.
   PubMed Web of Science ®Google Scholar
• Sreedhara AS, Kalmara E, Csermelya P, et al. Hsp90 isoforms: functions, expression and clinical importance. FEBS Letters. 2004;562(1–3):11–15.
   PubMed Web of Science ®Google Scholar
• Bhat R, Tummalapalli SR, Rotella DP. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. J Med Chem. 2014;57(21):8718–8728.
   PubMed Web of Science ®Google Scholar
• Verma S, Goyal S, Jamal S, et al. Hsp90: friends, clients and natural foes. Biochimie. 2016;127:227–240.
   PubMed Web of Science ®Google Scholar
• Seo YH. Organelle-specific Hsp90 inhibitors. Arch Pharm Res. 2015;38(9):1582–1590.
   PubMed Web of Science ®Google Scholar
• Wang X, Song X, Zhuo W, et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A. 2009;106(50):21288–21293.
   PubMed Web of Science ®Google Scholar
• Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007;98(10):1536–1539.
   PubMed Web of Science ®Google Scholar
• Tsutsumi S, Scroggins B, Koga F, et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene. 2008;27(17):2478–2487.
   PubMed Web of Science ®Google Scholar
• Özgür A, Tutar Y. Heat shock protein 90 inhibition in cancer drug discovery: from chemistry to futural clinical applications. Anticancer Agents Med Chem. 2016;16(3):280–290.
   PubMed Web of Science ®Google Scholar
• Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008;15(26):2702–2717.
   PubMed Web of Science ®Google Scholar
• Butler LM, Ferraldeschi R, Armstrong HK, et al. Maximizing the therapeutic potential of HSP90 Inhibitors. Mol Cancer Res. 2015;13(11):1445–1451.
   PubMed Web of Science ®Google Scholar
• Gewirth DT. Paralog specific Hsp90 Inhibitors - A brief history and a bright future. Curr Top Med Chem. 2016;16(25):2779–2791.
   PubMed Web of Science ®Google Scholar
• Lavery LA, Partridge JR, Ramelot TA, et al. Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism. Mol Cell. 2014;53(2):330–343.
   PubMed Web of Science ®Google Scholar
• Partridge JR, Lavery LA, Elnatan D, et al. A novel N-terminal extension in mitochondrial TRAP1 serves as a thermal regulator of chaperone activity. eLife. 2014;3:e03487.
   Web of Science ®Google Scholar
• Song HY, Dunbar JD, Zhang YX, et al. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J Biol Chem. 1995;270(8):3574–3581.
   PubMed Web of Science ®Google Scholar
• Felts SJ, Owen BA, Nguyen P, et al. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem. 2000;275(5):3305–3312.
   PubMed Web of Science ®Google Scholar
• Kang BH, Plescia J, Dohi T, et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell. 2007;131(2):257–270.
   PubMed Web of Science ®Google Scholar
• Montesano Gesualdi N, Chirico G, Pirozzi G, et al. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress. 2007;10(4):342–350.
   PubMed Web of Science ®Google Scholar
• Costantino E, Maddalena F, Calise S, et al. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett. 2009;279(1):39–46.
   PubMed Web of Science ®Google Scholar
• Amoroso MR, Matassa DS, Laudiero G, et al. TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. Cell Death Differ. 2012;19(4):592–604.
   PubMed Web of Science ®Google Scholar
• Matassa DS, Amoroso MR, Agliarulo I, et al. Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. Cell Death Dis. 2013;4:e851.
   PubMed Web of Science ®Google Scholar
• Palladino G, Notarangelo T, Pannone G, et al. TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells. Endocr Relat Cancer. 2016;23(9):699–709.
   PubMed Web of Science ®Google Scholar
• Sisinni L, Maddalena F, Condelli V, et al. TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination. J Pathol. 2017 Jul 5. DOI:10.1002/path.4936. [Epub ahead of print].
   PubMedGoogle Scholar
• Sciacovelli M, Guzzo G, Morello V, et al. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab. 2013;17(6):988–999.
   PubMed Web of Science ®Google Scholar
• Chae YC, Angelin A, Lisanti S, et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2013;4:2139.
   PubMed Web of Science ®Google Scholar
• Lisanti S, Tavecchio M, Chae YC, et al. Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks. Cell Rep. 2014;8(3):671–677.
   PubMed Web of Science ®Google Scholar
• Chen CF, Chen Y, Dai K, et al. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol Cell Biol. 1996;16(9):4691–4699.
   PubMed Web of Science ®Google Scholar
• Condelli V, Piscazzi A, Sisinni L, et al. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. Cancer Res. 2014;74(22):6693–6704.
   PubMed Web of Science ®Google Scholar
• Maddalena F, Sisinni L, Lettini G, et al. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol. 2013;7(5):895–906.
   PubMed Web of Science ®Google Scholar
• Landriscina M, Laudiero G, Maddalena F, et al. Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res. 2010;70(16):6577–6586.
   PubMed Web of Science ®Google Scholar
• Lettini G, Sisinni L, Condelli V, et al. TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma. Cell Death Differ. 2016;23(11):1792–1803.
   PubMed Web of Science ®Google Scholar
• Matassa DS, Agliarulo I, Amoroso MR, et al. TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: relevance in human colorectal tumors. Mol Oncol. 2014;8:1482–1494.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tsutsumi S, Muhlebach G, et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A. 2013;110(17):E1604–12.
   PubMed Web of Science ®Google Scholar
• Simmons AD, Musy MM, Lopes CS, et al. A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses. Hum Mol Genet. 1999;8(12):2155–2164.
   PubMed Web of Science ®Google Scholar
• Agliarulo I, Matassa DS, Amoroso MR, et al. TRAP1 controls cell migration of cancer cells in metabolic stress conditions: correlations with AKT/p70S6K pathways. Biochim Biophys Acta. 2015;1853(10 Pt A):2570–2579.
   PubMed Web of Science ®Google Scholar
• Amoroso MR, Matassa DS, Sisinni L, et al. TRAP1 revisited: novel localizations and functions of a ‘next-generation’ biomarker (review). Int J Oncol. 2014;45(3):969–977.
   PubMed Web of Science ®Google Scholar
• Maddalena F, Simeon V, Vita G, et al. TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. Oncotarget. 2017 Feb 3. DOI:10.18632/oncotarget.15070.
   PubMed Web of Science ®Google Scholar
• Gao JY, Song BR, Peng JJ, et al. Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer. World J Gastroenterol. 2012;18:5965–5971.
   PubMed Web of Science ®Google Scholar
• Leav I, Plescia J, Goel HL, et al. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol. 2010;176(1):393–401.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang J, Huang Z, et al. Aberrantly upregulated TRAP1 is required for tumorigenesis of breast cancer. Oncotarget. 2015;6(42):44495–44508.
   PubMed Web of Science ®Google Scholar
• Agorreta J, Hu J, Liu D, et al. TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC. Mol Cancer Res. 2014;12(5):660–669.
   PubMed Web of Science ®Google Scholar
• Tian X, Ma P, Sui CG, et al. Suppression of tumor necrosis factor receptor-associated protein 1 expression induces inhibition of cell proliferation and tumor growth in human esophageal cancer cells. Febs J. 2014;281(12):2805–2819.
   PubMed Web of Science ®Google Scholar
• Fang W, Li X, Jiang Q, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008;6:32.
   PubMed Web of Science ®Google Scholar
• Han JJ, Baek SK, Lee JJ, et al. Combination of TRAP1 and ERCC1 expression predicts clinical outcomes in metastatic colorectal cancer treated with oxaliplatin/5-Fluorouracil. Cancer Res Treat. 2014;46:55–64.
   PubMedGoogle Scholar
• Pak MG, Koh HJ, Roh MS. Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. Diagn Pathol. 2017;12(1):6.
   PubMed Web of Science ®Google Scholar
• Ou Y, Liu L, Xue L, et al. TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer. J Genet Genomics. 2014;41(10):529–537.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu Y, Cho K, et al. Downregulation of TRAP1 sensitizes glioblastoma cells to temozolomide chemotherapy through regulating metabolic reprogramming. Neuroreport. 2016;27(3):136–144.
   PubMed Web of Science ®Google Scholar
• Aust S, Bachmayr-Heyda A, Pateisky P, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer. 2012;11(9):69.
   PubMed Web of Science ®Google Scholar
• Amoroso MR, Matassa DS, Agliarulo I, et al. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. Cell Death Dis. 2016;7(12):e2522.
   PubMed Web of Science ®Google Scholar
• Matassa DS, Amoroso MR, Lu H, et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23(9):1542–1554.
   PubMed Web of Science ®Google Scholar
• Rasola A, Neckers L, Picard D. Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol. 2014;24(8):455–463.
   PubMed Web of Science ®Google Scholar
• Im CN. Past, present, and emerging roles of mitochondrial heat shock protein TRAP1 in the metabolism and regulation of cancer stem cells. Cell Stress Chaperones. 2016;21(4):553–562.
   PubMed Web of Science ®Google Scholar
• Condelli V, Maddalena F, Sisinni L, et al. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma. Oncotarget. 2015;6(26):22298–22309.
   PubMed Web of Science ®Google Scholar
• Masgras I, Ciscato F, Brunati AM, et al. Absence of neurofibromin induces an oncogenic metabolic switch via mitochondrial ERK-mediated phosphorylation of the chaperone TRAP1. Cell Rep. 2017;18(3):659–672.
   PubMed Web of Science ®Google Scholar
• Lisanti S, Garlick DS, Bryant KG, et al. Transgenic expression of the mitochondrial chaperone TNFR-associated protein 1 (TRAP1) accelerates prostate cancer development. J Biol Chem. 2016;291(48):25247–25254.
   PubMed Web of Science ®Google Scholar
• Liu D, Hu J, Agorreta J, et al. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett. 2010;296(2):194–205.
   PubMed Web of Science ®Google Scholar
• Sisinni L, Maddalena F, Lettini G, et al. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. Int J Oncol. 2014;44(2):573–582.
   PubMed Web of Science ®Google Scholar
• Basit F, Van Oppen LM, Schöckel L, et al. Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis. 2017;8(3):e2716.
   PubMedGoogle Scholar
• Hu J, Tan EY, Campo L, et al. TRAP1 is involved in cell cycle regulated by Retinoblastoma susceptibility gene (RB1) in early hypoxia and has variable expression patterns in human tumors. J Cancer Res Updates. 2013;2:194–210.
   Google Scholar
• Chae YC, Caino MC, Lisanti S, et al. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell. 2012;22(3):331–344.
   PubMed Web of Science ®Google Scholar
• Solárová Z, Mojžiš J, Solár P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol. 2015;46(3):907–926.
   PubMed Web of Science ®Google Scholar
• Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 1997;89(2):239–250.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Singh EK, Nazarova LA, et al. Macrocyclic inhibitors of hsp90. Curr Top Med Chem. 2010;10(14):1380–1402.
   PubMed Web of Science ®Google Scholar
• Soga S, Shiotsu Y, Akinaga S, et al. Development of radicicol analogues. Curr Cancer Drug Targets. 2003;3(5):359–369.
   PubMed Web of Science ®Google Scholar
• Lundgren K, Zhang H, Brekken J, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009;8(4):921–929.
   PubMed Web of Science ®Google Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009;106(20):8368–8373.
   PubMed Web of Science ®Google Scholar
• Le Bras G, Radanyi C, Peyrat JF, et al. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J Med Chem. 2007;50(24):6189–6200.
   PubMed Web of Science ®Google Scholar
• Radanyi C, Le Bras G, Marsaud V, et al. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett. 2009;274(1):88–94.
   PubMed Web of Science ®Google Scholar
• Samadi AK, Zhang X, Mukerji R, et al. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett. 2011;312(2):158–167.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Taldone T, Modi S, et al. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823(3):742–755.
   PubMed Web of Science ®Google Scholar
• Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64–76.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Plescia J, Raskett CM, et al. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther. 2010;9(6):1638–1646.
   PubMed Web of Science ®Google Scholar
• Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100(24):13791–13796.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46–54.
   PubMed Web of Science ®Google Scholar
• Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7(5):457–468.
   PubMed Web of Science ®Google Scholar
• Siegelin MD. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer? Cancer Lett. 2013;333(2):133–146.
   PubMed Web of Science ®Google Scholar
• Kang BH, Plescia J, Song HY, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest. 2009;119(3):454–464.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Dohi T, Raskett CM, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011;121(4):1349–1360.
   PubMed Web of Science ®Google Scholar
• Münch C, Harper JW. Mitochondrial unfolded protein response controls matrix pre-RNA processing and translation. Nature. 2016;534(7609):710–713.
   PubMed Web of Science ®Google Scholar
• Rambold AS, Lippincott-Schwartz J. Mechanisms of mitochondria and autophagy crosstalk. Cell Cycle. 2011;10(23):4032–4038.
   PubMed Web of Science ®Google Scholar
• Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12(2):119–131.
   PubMed Web of Science ®Google Scholar
• Kang BH, Tavecchio M, Goel HL, et al. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br J Cancer. 2011;104(4):629–634.
   PubMed Web of Science ®Google Scholar
• Sung N, Lee J, Kim JH, et al. Mitochondrial Hsp90 is a ligand-activated molecular chaperone coupling ATP binding to dimer closure through a coiled-coil intermediate. Proc Natl Acad Sci U S A. 2016;113(11):2952–2957.
   PubMed Web of Science ®Google Scholar
• Lee C, Park HK, Jeong H, et al. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. J Am Chem Soc. 2015;137(13):4358–4367.
   PubMed Web of Science ®Google Scholar
• Baruchello R, Simoni D, Grisolia G, et al. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90. J Med Chem. 2011;54(24):8592–8604.
   PubMed Web of Science ®Google Scholar
• Baruchello R, Simoni D, Marchetti P, et al. 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors. Eur J Med Chem. 2014;76:53–60.
   PubMed Web of Science ®Google Scholar
• Menezes DL, Taverna P, Jensen MR, et al. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther. 2012;11(3):730–739.
   PubMed Web of Science ®Google Scholar
• Zitzmann K, Ailer G, Vlotides G, et al. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Int J Oncol. 2013;43(6):1824–1832.
   PubMed Web of Science ®Google Scholar
• D’Annessa I, Sattin S, Tao J, et al. Design of allosteric stimulators of the HSP90 ATPase as novel anticancer leads. Chemistry. 2017 Feb 16. DOI:10.1002/chem.201700169.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang T, Schwartz SJ, et al. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat. 2009;12(1–2):17–27.
   PubMed Web of Science ®Google Scholar
• Leskovar A, Wegele H, Werbeck ND, et al. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J Biol Chem. 2008;283(17):11677–11688.
   PubMed Web of Science ®Google Scholar